Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Collaboration › Details

Broken String Biosciences–Zyme Communications: public relations, 202309 service existent by Zyme

 

Period Period 2023-09-18
Organisations Partner, 1st Broken String Biosciences Ltd.
  Partner, 2nd Zyme Communications Ltd.
Products Product public relations / investor relations / marcom (services)
  Product 2 INDUCE-seq™ DNA break mapping technology
Person Person Jeffery, Lily (Zyme Communications 201708– Account Executive)
     

Broken String Biosciences Ltd.. (9/18/23). "Press Release: Broken String Biosciences Closes $15M Series A Funding Round". Cambridge.

> Funds to support further development and commercialization of the Company’s INDUCE-seq DNA break mapping technology

> Platform technology provides in situ off-target measurement in clinically relevant cells to accelerate the progression of cell and gene therapy programs

> New investors include Illumina Ventures, Mérieux Equity Partners, and HERAN Partners


Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures). As part of the round, Yoann Bonnamour, Mérieux Equity Partners, and Arnaud Autret, Illumina Ventures, join the Company’s Board of Directors.

The Series A funding will be used to develop Broken String’s Next Generation Sequencing (NGS)-based DNA break mapping platform, INDUCE-seq™, into a scalable ‘Platform as a Service’ (PaaS) offering and to expand its capabilities beyond gene editing, broadening its go-to-market strategy and driving commercial traction. The investment also supports the Company’s ongoing growth, including recruitment for its UK team based at the Wellcome Genome Campus, Cambridge, and the establishment of a US office.

The progress of cell and gene therapies based on genome editing technologies, such as CRISPR-Cas9, requires stringent pre-clinical assessments of off-target editing events. INDUCE-seq enables researchers to assess the specificity of genome editing tools and evaluate the associated off-target genetic outcomes. The platform technology addresses the limitations of existing gene editing off-target measurement approaches; leveraging a novel polymerase chain reaction (PCR)-free approach to directly measure and quantify DNA double-strand breaks using NGS (1). It provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to unlock new therapeutic targets within the genome and to advance gene editing programs.

Felix Dobbs, PhD, Chief Executive Officer of Broken String Biosciences, commented: “Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients. Operating at the intersection of biology, bioinformatics and data science, our INDUCE-seq platform offers an unbiased, end-to-end solution that expedites the measurement and assessment of off-target gene editing during therapeutic development. This provides essential information required to progress therapeutic programs that leverage gene editing and mitigate potential risks that can result in later-stage clinical failures. By developing a deployable PaaS offering, we have the opportunity to provide the cell and gene therapy community with this much-needed solution and achieve rapid market growth.” He continued: “The support Broken String has received from leading life science and genomics investors demonstrates the potential of our technology and its ability to deliver on the therapeutic promise of gene editing.”

Arnaud Autret, PhD, Principal at Illumina Ventures, said: “The clinical progression of cell and gene therapies is held back by off-target safety concerns – we recognize the power of Broken String Biosciences’ technology to drive advances in safer genome editing, genome biology and genetic toxicology, and optimize drug development programs. The platform has the potential to become the gold-standard solution for measuring off-target gene editing.”

Yoann Bonnamour, Investment Manager at Mérieux Equity Partners, commented: “The gene therapy market, and the essential off-target assessment technology alongside it, is a rapidly growing opportunity. Broken String Biosciences’ team has the technical expertise and resources, paired with its strong connection with a world-leading genomics research institute, to drive this platform forward and transform the way gene editing programs are designed and developed.”

Raf Roelands, Investment Director at HERAN Partners, added: “Broken String Biosciences’ INDUCE-seq technology platform is a game-changing innovation for the characterization of off-target genome breaks. The team has made impressive progress since its seed funding round in 2021, successfully demonstrating that the platform addresses the market’s needs and generates repeat revenues across a portfolio of partners. This new funding will enable the technology to be developed and delivered in a format that meets the needs of all customers, ideally positioning the Company for significant growth.”


https://www.nature.com/articles/s41467-022-31702-9


To learn more about Broken String Biosciences, please visit brokenstringbio.com


ENDS


Image: Felix Dobbs, PhD, CEO, Broken String Biosciences
For a high-resolution image, please contact Zyme Communications.


Media Contact

Lily Jeffery
Zyme Communications
E: lily.jeffery@zymecommunications.com
T: +44 (0) 07891 477 378


Broken String Biosciences
Felix Dobbs, PhD
CEO, Broken String Biosciences
E: info@brokenstringbio.com
T: +44 (0) 1223 786 071


To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.


About Broken String Biosciences

Broken String Biosciences is a genomics company with the goal of developing safer cell and gene therapies by assessing the stability of the genome. The Company is building a technology platform pipeline that will drive the development of cell and gene therapies that are safer by design. Its core technology, INDUCE-seq™, is a Next Generation Sequencing (NGS)-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and to evaluate the associated genetic outcomes. The platform technology provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to unlock new therapeutic targets within the genome and to advance gene editing programs.

Broken String Biosciences was spun out of Cardiff University in 2020 and completed a six-month residency at the Illumina Accelerator in Cambridge, UK. In September 2021, the Company closed a Series Seed financing of c.$4m USD with investors from the UK, Germany and the US.

Broken String Biosciences has established strong links with several academic and industrial collaborators and is headquartered at the BioData Innovation Centre, Wellcome Genome Campus, Cambridge, UK, with laboratory premises nearby at Chesterford Research Park. 

To find out more, visit: www.brokenstringbio.com, follow Broken String Biosciences on LinkedIn, and @BrokenStringBio on Twitter.


About Illumina Ventures

Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN). As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, personal wellness and sustainability. For more information, visit illuminaventures.com.


About Mérieux Equity Partners

Mérieux Equity Partners ("MxEP") is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages over € 1.5 billion in assets and co-leads this financing round with its latest Venture Capital fund, OMX Europe Venture Fund, with the co-sponsorship of Korys. For more information, visit merieux-partners.com.


About HERAN Partners

HERAN Partners is a Belgium-based investment fund focused on supporting European start-ups and scale-ups in the MedTech and HealthTech industries. In addition to financial support, they provide a strong network, expertise, and mentorship in order to fuel growth at their portfolio companies. HERAN currently manages its first fund of EUR 75.5m, which targets ventures with highly-disruptive and scalable technologies. For more information, visit heranpartners.com.

   
Record changed: 2023-09-22

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Broken String Biosciences Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top